SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE U.K. LAUNCH OF 'LEUCOMAX'
SCHERING-PLOUGH AND SANDOZ PHARMA ANNOUNCE U.K. LAUNCH OF 'LEUCOMAX' MADISON, N.J., Oct. 29 /PRNewswire/ -- Schering-Plough Corporation (NYSE: SGP) of Madison, N.J., and Sandoz Pharma Ltd. of Basel, Switzerland, announced today the launch in the United Kingdom of 'Leucomax' (molgramostim), a granulocyte macrophage colony stimulating factor (GM-CSF). The United Kingdom is the first European Community (EC) country to approve the product since it was recommended for approval in September by the EC's Committee for Proprietary Medicinal Products (CPMP). The product was jointly developed by Sandoz and Schering-Plough and will be co-marketed in the EC by the two companies. 'Leucomax' represents an advance in cancer therapy, offering the potential to reduce morbidity and lessen the risk of infection in individuals whose immune systems are compromised. GM-CSF is one of a group of natural proteins that broadly stimulate the production of white blood cells, a key element of the body's defense against infection. The 'Leucomax' application was filed in August 1990 with the Medicines Control Agency of the United Kingdom, which served as the rapporteur country for the CPMP. The CPMP is the EC body for the review of applications for biotechnology and high-technology products. The Medicines Control Agency approved 'Leucomax' in hospitals for chemotherapy-induced neutropenia in cancer patients, to accelerate recovery after autologous bone marrow transplantation, and to combat ganciclovir (DHPG)-induced neutropenia in AIDS patients with cytomegalovirus retinitis, which in most cases leads to blindness. In addition to the United Kingdom, 'Leucomax' is marketed in Argentina, Ecuador, Finland, Israel, Mexico, Pakistan and Sweden, and approved for marketing in Chile, Norway and Russia. Schering-Plough and Sandoz have filed marketing applications for 'Leucomax' in most major countries. Sandoz and Schering-Plough are research-based companies engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide. -0- 10/29/92 /CONTACT: Steve Galpin Jr. of Schering-Plough, 201-822-7415, or Sandoz Press Office, 41-61-324-9001/ (SGP) CO: Schering-Plough Corporation ST: New Jersey IN: MTC SU: PDT
SH -- NY011 -- 6414 10/29/92 09:03 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Oct 29, 1992|
|Previous Article:||SUNRISE MEDICAL REPORTS RECORD FIRST QUARTER EARNINGS|
|Next Article:||MASCO CORPORATION ANNOUNCES RECORD QUARTERLY SALES, IMPROVED EARNINGS AND DIVIDEND INCREASE|